← All trials
NCT05701241
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 28, 2023
- Primary completion
- Apr 30, 2029
- Completion date
- Apr 30, 2034
- First posted
- Jan 27, 2023
- Last posted
- Jul 12, 2023
- Enrollment
- 270
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of AntwerpLead sponsor
- ZonMw: The Netherlands Organisation for Health Research and DevelopmentCollaborator
- Katholieke Universiteit LeuvenCollaborator
- Erasmus University RotterdamCollaborator
- University of AntwerpOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.